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Efficacy of low dose levo dopa in treatment of TD has been studied on 30 male inpatients with prede« 
fined selection criteria. The preliminary results are encouraging but long term double blind studies iu 
larger samples are needed. 
Tardive dyskinesia severe enough to 
interfere with talking, swallowing or 
mobility is relatively rare. But even in 
mild case* they may constitute a severe 
social handicap. Jeste and Wyatt (1982) 
after reviewing 285 treatment studies 
involving more than 3000 patients con-
cluded that no satisfactory treatment for 
persistent TD is available. The tradi-
tional hypothesis of dopamine (DA) over-
activity and receptor supersensitivity 
(Casey and Robins, 1978; Christensen et 
al,. 1970; Tarsy etal., 1979) has dominated 
and shaped various treatment approa-
ches. 
An alternative approach to the treat-
ment of TD is levodopa, a metabolic 
precursor of dopamine. It has been pro-
posed that low doses of levodopa leads to 
stimulation of presyneptic DA receptors, 
which in turn reduces the synthesis and 
turnover of DA, thereby inhibiting DA 
neurotransmission (Caroll et al., 1977). 
Alpert and Friedhoff (1980) on the other 
hand, suggest that treatment with levo-
dopa temporarily increases DA levels and 
thus reduces dopamine receptor supersen-
sitivity. The use of levodopa or other 
DA agonist may have additional adva-
tage in their ability to counteract the 
intial extrapyramidal side effects e. g. 
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akathisia and rigidity with consequent 
greater emotional participation and feel-
ing of well-being. The incidence of a 
worsening of psychosis is reported to be 
high but this may be particularly seen 
with high dose levodopa administration. 
The present study was conducted to 
find out the efficacy of low dose levodopa 
treatment in TD. 
Material and Methods 
The study was conducted at the Cen-
tral Institute of Psychiatry, Ranchi. As 
a first step all chronically hospitalized 
male inpatients were screened for the 
presence of any movement disorder. 
30 patients were selected for the study 
using the following inclusion criteria— 
(1) a firm diagnosis of TD on administra-
tion of the Abnormal Involuntary Move-
ment Scale (AIMS) twice a week for two 
weeks (2) no change in neuroleptic treat-
ment during the last three months (3) 
physically fit to undergo the trial (4) 
cooperative enough to take oral medica-
tion (5) baseline investigations within 
normal limits (6) informed consent. The 
exclusion criteria were (1) age more than 
60 years (2) presence of schizophrenic 
mannerisms and stereotypies (3) those 
suffering from neurological movement 
Central Institute of Psychiatry, Ksrake, Ranchi-
834006. 242  SUJATA SETHI el at. 
disorders like Huntington's chorea or 
organic brain syndrome. 
AH the 30 patients thus selected were 
assessed on the Rockland Research Insti-
tute Abbreviated Dyskinesia Rating Scale 
(Simpson et al., 1980) and Brief Psychia-
tric Rating Scale (Overall and Gorham, 
1962). All patients received a placebo 
for 6 weeks and then after a wash out 
period of one week they received levodopa 
(1500 mg/day). 
Intervention was in the form of a 
single tablet of placebo or levodopa (500 
mg) thrice a day following meals. The 
dose and type of neuroleptic used was kept 
constant during the entire period of 
study. 
During the period of study, dyskine-
sia rating scale was administered at weekly 
intervals for 14 weeks from the onset of 
placebo administration to one week follo-
wing the discontinuation of levodopa. 
This method was adopted in order to 
account for the spontaneous improvement 
seen in many patients with TD (Rex Roth 
and Berger, 1980). BPRS was readmini-
stered at the end of the trial with placebo 
and levodopa. 
The side effects and symptom check-
list of WHO was used once a week to re-
«ord any side effect. 
Results 
The mean age of the sample was 46.7 
years with a standard deviation of 8.8 
(range 32 to 57 years). The mean dura-
tion of illness was 24.5 (±8.8) years. 
They were on neuroleptic therapy for a 
mean duration of 15 (±7.07) years, with 
a mean total neuroleptic dose of 1277.17 
(±734.39) gm of chlorpromazine equiva-
lent. The mean number of drug holidays 
were 8.8 (±6.22). 
Out of the 30 patients selected, 29 
completed the study. One patient while 
on levodopa showed an exacerbation of 
psychiatric symptomatology severe enough 
to warrant increase in the dose of neuro-
leptic and was dropped from the study. 
Another patient showed aggressive beha-
viour once during the trial period but 
could complete the study satisfactorily. 
No patient showed any physical side 
effects during the trial period. 
In order to determine the number of 
cases who responded favourably, improve-
ment was defined as a minimum of 50% 
reduction in symptoms, as suggested by 
Jeste and Wyatt (1982). Data was pro-
cessed and analysed using two tailed t-test 
for significance. 
No significant change was seen with 
placebo. Levodopa administration how-
ever led to improvement in TD scores in 
79.3 % of the sample. The difference was 
statistically significant. One week follo-
wing discontinuation of levodopa adminis-
tration there was no significant increase 
in TD scores (Table I). 
TABLE I—Showing significance of difference of 
mean scores on dyskinesia rating scale 
of various stages of the study 
Phase of the study Mean SD 
On Placebo 
Initial score 31.5 9.71 
Final score 31.6 10.30 
t=0.33, d.f. =28, N. S. 
On levodopa 
Initial score 33.6 10.30 
Final score 17.6 5.80 
t=8.33, d. f.=28, p<0.01 
On Discontinuation of levodopa 
Initial score 17.6 5.80 
Final score 18.0 5.16 
t = 1.4,d.f.=28, N. S. 
Discussion 
Jeste and Wyatt (1982) found 11 
studies on the effects of oral administra-LOW DOSE LEVODOPA IN TRARDIVE DYSKINESIA  US 
tion of levodopa in patients with TD. 
Only 33% of the patients treated had 
improved; in others dyskinesia was either 
unimproved or worsened. They conclu-
ded that the hypothesis behind levodopa 
administration is attractive but the in-
cidence of various side effects (including 
of psychosis) is rather high. 
Several investigators have suggested 
that there may be a biphasic response to 
levodopa administration (Smith et al., 
1977, Caroll et al., 1977). Worsening of 
psychosis is also seen more often with 
high doses. Tarsy et al. (1979) gave 
levodopa in different doses to 10 pa-
tients with TD and reported improve-
ment with low doses and worsen-
ing at high doses. Friedhoff and Alpert 
(1975) using higher doses reported in-
itially a worsening of tardive symptoms 
but after repeated administration with a 
subsequent withdrawal, a decrease in 
abnormal movements. 
The present study used a fixed low 
doses levodopa treatment strategy throu-
ghout the 6 Week trial period, and in or-
der to take care of natural variation seen 
in many patients with TD, a 6 w«ek trial 
with placebo preceded the levodopa treat-
ment. Significant improvement (defined 
as more than 50% reduction in symptoms) 
was found in 79.3% of patients with tar-
dive dyskinesia. Care was taken not to 
make any change in the current neurolep-
tic treatment. Serious worsening of psy-
chosis was seen in only one case. Howe-
ver, the study sample consisted of only 
male patients as gender is thought to be 
an important risk factor. Similarly, com-
pared to earlier studies, the mean age of 
the sample is lower (46.7±8.8 years). 
Age related changes in the brain is reco-
gnised as an important non-pharmaco-
logical phenomena contributing to the 
etiology of TD. Some of the discrepan-
cies in therapeutic trials in TD could be 
accounted towards these factors. 
Though the preliminary results are 
encouraging, long term double blind stu-
dies using larger samples of both sexes are 
needed in order to establish low doses 
levodopa administration as a valid thera-
peutic strategy in patients with TD. 
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